View Cart  

Analyst Support for Salix’s Relistor sNDA Sags as FDA Demands New Trial

A A
Citing cardiovascular safety concerns, the FDA says Salix Pharmaceuticals must conduct a large, well-controlled, chronic administration trial if its sNDA for opioid-induced constipation (OIC) drug Relistor is to advance.

To View This Article:

Login

Subscribe To Drug Industry Daily